These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ...
Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles. Traditional therapies ...
BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) ...
The last time I spoke about INmune Bio (INMB) it was with a Seeking Alpha article entitled "INmune Bio: Alzheimer's Disease Treatment Lottery Ticket". With this article, I noted its prospects about ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback